```
=> d que stat l16
L5          3 SEA FILE=REGISTRY ABB=ON  (OSELTAMIVIR PHOSPHATE OR ZANAMIVIR
              OR RJW-270201 OR RJW 270201 OR RJW270201 OR BCX-1812 OR
              BCX1812 OR BCX 1812)
L6        470 SEA FILE=HCAPLUS ABB=ON  (L5 OR OSELTAMIVIR PHOSPHATE OR
              ZANAMIVIR OR RJW-270201 OR RJW 270201 OR RJW270201 OR BCX-1812
              OR BCX1812 OR BCX 1812)
L8        414 SEA FILE=HCAPLUS ABB=ON  L6 AND (?BACT? OR ?PNEUMONIA? OR
              ?VIRAL? OR ?VIRUS?)
L9         17 SEA FILE=HCAPLUS ABB=ON  L8 AND (?PNEUMONIA? AND (?VIRUS? OR
              ?VIRAL?))
L13     48777 SEA FILE=HCAPLUS ABB=ON  (CEFTRIAXONE OR CEFOTAXIME OR
              VANCOMYCIN OR MEROPENEM OR CEFEPIME OR CEFTAZIDIME OR CEFUROXIM
              E OR NAFCILLIN OR OXACILLIN OR AMPICILLIN OR TICARCILLIN OR
              TIMENTIN OR UNASYN OR AZITHROMYCIN OR TRIMETHOPRIM SULFAMETHOXA
              ZOLE OR CLINDAMYCIN OR CIPROFLOXACIN OR LEVOFLOXACIN OR
              SYNERCID)
L14     52930 SEA FILE=HCAPLUS ABB=ON  L13 OR AMOXICILLIN OR AUGMENTIN OR
              CEFUROXIME OR TRIMETHOPRIM SULFAMETHOXAZOLE OR AZITHROMYCIN OR
              CLINDAMYCIN OR DICLOXACILLIN OR CIPROFLOXACIN OR LEVOFLOXACIN
              OR CEFIXIME OR CEFPODOXIME OR LORACARBEF OR CEFADROXIL OR
              CEFABUTIN OR CEFDINIR OR CEPHRADINE
L15         7 SEA FILE=HCAPLUS ABB=ON  L9 AND (?ANTIBIOTIC? OR L14)
L16         2 SEA FILE=HCAPLUS ABB=ON  L15 AND (PRD<20010927 OR PD<20010927)

=> d ibib abs l16 1-2

L16  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2001:208067  HCAPLUS
DOCUMENT NUMBER:          134:242657
TITLE:                    Use of CSAIDs (cytokine suppressive antiinflammatory
                          drugs) in rhinovirus infection
INVENTOR(S):              Dillon, Susan B.; Griego, Sandra D.
PATENT ASSIGNEE(S):       Smithkline Beecham Corp., USA
SOURCE:                   PCT Int. Appl., 30 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2001019322         A2    20010322    WO 2000-US25386         20000915 <--
     WO 2001019322         A3    20011004
         W:  AE, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CZ, DZ, EE, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG,
             MK, MN, MX, MZ, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA,
             US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2385722            AA    20010322    CA 2000-2385722         20000915 <--
     AU 2000075845         A5    20010417    AU 2000-75845           20000915 <--
     EP 1223924            A2    20020724    EP 2000-965060          20000915 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     TR 200200673          T2    20021223    TR 2002-200200673       20000915 <--
     JP 2003516314         T2    20030513    JP 2001-522960          20000915 <--
     BR 2000014041         A     20030715    BR 2000-14041           20000915 <--
```

ZA 2002002060	A	20030312	ZA 2002-2060	20020313 <--
NO 20020001301	A	20020516	NO 2002-1301	20020315 <--
PRIORITY APPLN. INFO.:			US 1999-154494P	P 19990917 <--
			WO 2000-US25386	W 20000915 <--

AB The present invention is directed to the novel use of a CSBP/p38 kinase inhibitor for the treatment of symptoms of the common cold and the exacerbation of symptoms associated therewith in humans. The effect of a compound trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yl]imidazole on the rhinovirus-induced cytokine production by epithelial cells was examined

L16 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2001:136991 HCAPLUS
DOCUMENT NUMBER:	134:198075
TITLE:	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
INVENTOR(S):	Patel, Mahesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S):	Lipocine, Inc., USA
SOURCE:	PCT Int. Appl., 113 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	13
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012155	A1	20010222	WO 2000-US18807	20000710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6309663	B1	20011030	US 1999-375636	19990817
CA 2380642	AA	20010222	CA 2000-2380642	20000710 <--
EP 1210063	A1	20020605	EP 2000-947184	20000710 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506476	T2	20030218	JP 2001-516502	20000710 <--
NZ 517659	A	20041224	NZ 2000-517659	20000710 <--
AU 780877	B2	20050421	AU 2000-60838	20000710 <--
US 2001024658	A1	20010927	US 2000-751968	20001229 <--
US 6458383	B2	20021001		
PRIORITY APPLN. INFO.:			US 1999-375636	A 19990817 <--
			WO 2000-US18807	W 20000710 <--

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18,

and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d que stat l21
L5          3 SEA FILE=REGISTRY ABB=ON  (OSELTAMIVIR PHOSPHATE OR ZANAMIVIR
                OR RJW-270201 OR RJW 270201 OR RJW270201 OR BCX-1812 OR
                BCX1812 OR BCX 1812)
L6        470 SEA FILE=HCAPLUS ABB=ON  (L5 OR OSELTAMIVIR PHOSPHATE OR
                ZANAMIVIR OR RJW-270201 OR RJW 270201 OR RJW270201 OR BCX-1812
                OR BCX1812 OR BCX 1812)
L8        414 SEA FILE=HCAPLUS ABB=ON  L6 AND (?BACT? OR ?PNEUMONIA? OR
                ?VIRAL? OR ?VIRUS?)
L9         17 SEA FILE=HCAPLUS ABB=ON  L8 AND (?PNEUMONIA? AND (?VIRUS? OR
                ?VIRAL?))
L13     48777 SEA FILE=HCAPLUS ABB=ON  (CEFTRIAXONE OR CEFOTAXIME OR
                VANCOMYCIN OR MEROPENEM OR CEFEPIME OR CEFTAZIDIME OR CEFUROXIM
                E OR NAFCILLIN OR OXACILLIN OR AMPICILLIN OR TICARCILLIN OR
                TIMENTIN OR UNASYN OR AZITHROMYCIN OR TRIMETHOPRIM SULFAMETHOXA
                ZOLE OR CLINDAMYCIN OR CIPROFLOXACIN OR LEVOFLOXACIN OR
                SYNERCID)
L14     52930 SEA FILE=HCAPLUS ABB=ON  L13 OR AMOXICILLIN OR AUGMENTIN OR
                CEFUROXIME OR TRIMETHOPRIM SULFAMETHOXAZOLE OR AZITHROMYCIN OR
                CLINDAMYCIN OR DICLOXACILLIN OR CIPROFLOXACIN OR LEVOFLOXACIN
                OR CEFIXIME OR CEFPODOXIME OR LORACARBEF OR CEFADROXIL OR
                CEFABUTIN OR CEFDINIR OR CEPHRADINE
L15         7 SEA FILE=HCAPLUS ABB=ON  L9 AND (?ANTIBIOTIC? OR L14)
L17        98 SEA L15
L18        98 DUP REMOV L17 (0 DUPLICATES REMOVED)
L20        98 SEA L18 AND (?BACT?(W) ?INFECT? OR ?PNEUMONIA?)
L21         4 SEA L20 AND ?NEURAMINIDASE?(W) ?INHIBIT?

=> d ibib abs l21 1-4

L21  ANSWER 1 OF 4  EMBASE  COPYRIGHT (c) 2006 Elsevier B.V. All rights
     reserved on STN
ACCESSION NUMBER:  2003291437  EMBASE
TITLE:             Treatment of community-acquired lower respiratory tract
                   infections during pregnancy.
AUTHOR:            Lim W.S.; Macfarlane J.T.; Colthorpe C.L.
CORPORATE SOURCE:  Dr. W.S. Lim, Respiratory Infection Research Group,
                   Respiratory Medicine, Nottingham City Hospital, Hucknall
                   Road, Nottingham NG5 1PB, United Kingdom.
                   wlim2@ncht.trent.nhs.uk
SOURCE:            American Journal of Respiratory Medicine, (2003) Vol. 2,
                   No. 3, pp. 221-233. .
                   Refs: 116
                   ISSN: 1175-6365  CODEN: AJRMAG
COUNTRY:           New Zealand
DOCUMENT TYPE:     Journal; General Review
FILE SEGMENT:      004     Microbiology
                   010     Obstetrics and Gynecology
                   015     Chest Diseases, Thoracic Surgery and Tuberculosis
                   037     Drug Literature Index
                   038     Adverse Reactions Titles
                   052     Toxicology
LANGUAGE:          English
SUMMARY LANGUAGE:  English
ENTRY DATE:        Entered STN: 31 Jul 2003
                   Last Updated on STN: 31 Jul 2003
AB   The incidence of lower respiratory tract infection (LRTI) in women of
     child-bearing age is approximately 64 per 1000 population.  The spectrum
     of illness ranges from acute bronchitis, which is very common, through
     influenza virus infection and exacerbations of underlying lung
```

disease, to pneumonia, which, fortunately is uncommon (<1.5% LRTI), but can be severe. Acute bronchitis is generally mild, self-limiting and usually does not require antibacterial therapy. Influenza virus infection in pregnant women has been recently related to increased hospitalization for acute cardiorespiratory conditions. At present, the safety of the newer neuraminidase inhibitors for the treatment of influenza virus infection has not been established in pregnancy and they are not routinely recommended. In influenza virus infection complicated by pneumonia, antibacterial agents active against Staphylococcus aureus and Streptococcus pneumoniae superinfection should be used. There are few data on infective complications of asthma or COPD in pregnancy. The latter is rare, as patients with COPD are usually male and aged over 45 years. Management is the same as for nonpregnant patients. The incidence and mortality of pneumonia in pregnancy is similar to that in nonpregnant patients. Infants born to pregnant patients with pneumonia have been found to be born earlier and weigh less than controls. Risk factors for the development of pneumonia include anemia, asthma and use of antepartum corticosteroids and tocolytic agents. Based on the few available studies, the main pathogens causing pneumonia are S. pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae and viruses. β-Lactam and macrolide antibiotics therefore remain the antibiotics of choice in terms of both pathogen coverage and safety in pregnancy. In HIV-infected pregnant patients, recurrent bacterial pneumonia, but not Pneumocystis carinii pneumonia (PCP), is more common than in nonpregnant patients. Trimethoprim/sulfamethoxazole (cotrimoxazole) has not definitely been associated with adverse clinical outcomes despite theoretical risks. Currently it is still the treatment of choice in PCP, where mortality remains high. In conclusion, there are few data specifically related to pregnant women with different types of LRTI. Where data are available, no significant differences compared with nonpregnant patients have been identified. In considering the use of any therapeutic agent or investigation in pregnant patients with LRTI, safety aspects must be carefully weighed against potential benefit. Otherwise, management strategies should not differ from those for nonpregnant patients. Further research in this area is warranted.

L21 ANSWER 2 OF 4 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003147535 EMBASE
TITLE: Oseltamivir for treatment of influenza in healthy adults: Pooled trial evidence and cost-effectiveness model for Canada.
AUTHOR: O'Brien B.J.; Goeree R.; Blackhouse G.; Smieja M.; Loeb M.
CORPORATE SOURCE: Dr. B.J. O'Brien, Center for Evaluation of Medicines, 105 Main Street East, Hamilton, Ont. L8N 1G, Canada. obrienb@mcmaster.ca
SOURCE: Value in Health, (2003) Vol. 6, No. 2, pp. 116-125. .
Refs: 30
ISSN: 1098-3015 CODEN: VIHLFM
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 004 Microbiology
017 Public Health, Social Medicine and Epidemiology
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 17 Apr 2003
Last Updated on STN: 17 Apr 2003

AB Background: Influenza is a common viral respiratory infection that is associated with significant morbidity. Oseltamivir (Tamiflu) is a neuraminidase inhibitor - a new class of antiviral treatment for influenza where efficacy and safety has been established but cost-effectiveness is unknown. Methods: A decision analytic model was used to estimate the costs and effectiveness of two treatment scenarios for empiric management of otherwise healthy nonelderly patients, presenting with influenza-like illness (ILI) to primary care physicians in Canada: 1) where oseltamivir is reimbursed and on formulary for prescription; and 2) where oseltamivir is not on formulary. Outcomes are influenza-days averted and quality-adjusted life-years (QALYs) gained. Effectiveness, utility, and pneumonia complication risk estimates are by pooled analysis of patient-level data from four clinical trials. Unit cost information (Canadian dollars) was obtained from published sources in Ontario. Probabilistic sensitivity analysis was conducted using Monte Carlo simulation. Results: Of 2288 patients randomized, influenza was confirmed in 1575 (69%) and oseltamivir treatment reduced the mean time to symptom alleviation by 1.08 days (95% confidence interval [CI] 0.58-1.59). Infected patients treated with oseltamivir had higher utility scores (quality of life) than placebo patients over the 7 days of follow-up ($P < .05$). Cost per influenza-day averted with oseltamivir on formulary is $49 (95% CI 31-107) and the cost per QALY is $57,863 (95% CI $48,919-$70,149). Results are sensitive to the percentage of patients presenting to their physician beyond 48 hours from symptom onset who get oseltamivir and the prevalence of influenza among patients presenting with ILI. Conclusions: Oseltamivir for treatment of patients with ILI is potentially cost-effective if clinical diagnostic specificity for influenza observed in clinical trials is applicable to routine practice. More population-based information on the prevalence of influenza among early (<48 hours) presenters with ILI would be valuable.

L21 ANSWER 3 OF 4 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001147848 EMBASE
TITLE: The challenge of pneumonia in the elderly: Part 2.
AUTHOR: Chan E.D.; Fernandez E.
CORPORATE SOURCE: Dr. E.D. Chan, Univ. of Colorado Hlth. Sci. Ctr., Natl. Jewish Med. and Res. Center, Denver, CO, United States
SOURCE: Journal of Respiratory Diseases, (2001) Vol. 22, No. 4, pp. 236-247. .
Refs: 27
ISSN: 0194-259X CODEN: JRDIFQ
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis
020 Gerontology and Geriatrics
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 3 May 2001
Last Updated on STN: 3 May 2001

AB Since the etiology of infection is established in only about half of the patients with community-acquired pneumonia (CAP), therapy is

usually empiric. One approach to treatment for CAP in the elderly is to give a second- or third-generation cephalosporin, a β-lactam/β-lactamase inhibitor, or trimethoprim-sulfamethoxazole with or without a macrolide. Alternatively, a second- or third-generation cephalosporin may be combined with a macrolide or a fluoroquinolone. Empiric therapy for severe pneumonia should provide coverage for Legionella pneumophila as well as for Streptococcus pneumoniae and β-lactamase-positive Haemophilus influenzae. For elderly patients with pneumonia caused by influenza (including those who have received the influenza vaccine), treatment with amantadine; rimantadine; or a neuraminidase inhibitor, such as oseltamivir or zanamivir, is recommended.

L21 ANSWER 4 OF 4 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2000041247 EMBASE
TITLE: [Old and new antibiotics for resistant pathogens, antiviral agents against influenza].
MALADIES INFECTIEUSES D'ANCIENS ET DE NOUVEAUX ANTIBIOTIQUES POUR DES GERMES RESISTANTS. DES ANTIVIRAUX CONTRE LA GRIPPE.
AUTHOR: Erard Ph.
CORPORATE SOURCE: Dr. Ph. Erard, Departement de Medecine, Hopital des Cadolles, 2000 Neuchatel, Switzerland
SOURCE: Medecine et Hygiene, (19 Jan 2000) Vol. 58, No. 2284, pp. 117-123. .
Refs: 27
ISSN: 0025-6749 CODEN: MEHGAB
COUNTRY: Switzerland
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 006 Internal Medicine
037 Drug Literature Index
LANGUAGE: French
SUMMARY LANGUAGE: English; French
ENTRY DATE: Entered STN: 10 Feb 2000
Last Updated on STN: 10 Feb 2000

AB Antibiotic usage is responsible of the emergence of resistance bacteria which are frequency causing current infections such as pneumococci and staphylococci. New drugs are developed but their use should be restricted to infections which cannot be treated successfully by older drugs. It is like that the new neuraminidase inhibitors will change the management of influenza infections by practitioners. These drugs are effective and well tolerated. However, early diagnosis of influenza infections is at present based upon clinical criteria and remains uncertain. Some antibiotics, antiviral and vaccines currently undergoing clinical development are discussed.

```
=> d que stat l22
L5          3 SEA FILE=REGISTRY ABB=ON  (OSELTAMIVIR PHOSPHATE OR ZANAMIVIR
                OR RJW-270201 OR RJW 270201 OR RJW270201 OR BCX-1812 OR
                BCX1812 OR BCX 1812)
L6        470 SEA FILE=HCAPLUS ABB=ON  (L5 OR OSELTAMIVIR PHOSPHATE OR
                ZANAMIVIR OR RJW-270201 OR RJW 270201 OR RJW270201 OR BCX-1812
                OR BCX1812 OR BCX 1812)
L8        414 SEA FILE=HCAPLUS ABB=ON  L6 AND (?BACT? OR ?PNEUMONIA? OR
                ?VIRAL? OR ?VIRUS?)
L9         17 SEA FILE=HCAPLUS ABB=ON  L8 AND (?PNEUMONIA? AND (?VIRUS? OR
                ?VIRAL?))
L13     48777 SEA FILE=HCAPLUS ABB=ON  (CEFTRIAXONE OR CEFOTAXIME OR
                VANCOMYCIN OR MEROPENEM OR CEFEPIME OR CEFTAZIDIME OR CEFUROXIM
                E OR NAFCILLIN OR OXACILLIN OR AMPICILLIN OR TICARCILLIN OR
                TIMENTIN OR UNASYN OR AZITHROMYCIN OR TRIMETHOPRIM SULFAMETHOXA
                ZOLE OR CLINDAMYCIN OR CIPROFLOXACIN OR LEVOFLOXACIN OR
                SYNERCID)
L14     52930 SEA FILE=HCAPLUS ABB=ON  L13 OR AMOXICILLIN OR AUGMENTIN OR
                CEFUROXIME OR TRIMETHOPRIM SULFAMETHOXAZOLE OR AZITHROMYCIN OR
                CLINDAMYCIN OR DICLOXACILLIN OR CIPROFLOXACIN OR LEVOFLOXACIN
                OR CEFIXIME OR CEFPODOXIME OR LORACARBEF OR CEFADROXIL OR
                CEFABUTIN OR CEFDINIR OR CEPHRADINE
L15         7 SEA FILE=HCAPLUS ABB=ON  L9 AND (?ANTIBIOTIC? OR L14)
L22        18 SEA FILE=USPATFULL ABB=ON  L15 AND (PRD<20010927 OR PD<20010927
                )

=> d ibib abs l22 1-18

L22  ANSWER 1 OF 18  USPATFULL on STN
ACCESSION NUMBER:        2006:277  USPATFULL
TITLE:                   3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38
                         kinase inhibitors
INVENTOR(S):             Adams, Jerry L., Wayne, PA, UNITED STATES
                         Bower, Michael J., Audubon, PA, UNITED STATES
                         Boehm, Jeffrey C., King of Prussia, PA, UNITED STATES
                         Griswold, Don Edgar, North Wales, PA, UNITED STATES
                         Underwood, David C., Ambler, PA, UNITED STATES
PATENT ASSIGNEE(S):      SmithKline Beecham Corporation, Philadelphia, PA,
                         UNITED STATES (U.S. corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 6982270          B1   20060103
                         WO 2001038313            20010531            <--
APPLICATION INFO.:       US 2002-129863           20001121  (10)
                         WO 2000-US31874          20001121
                                                  20020510  PCT 371 date

                                NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 1999-166972P    19991123 (60)            <--
DOCUMENT TYPE:           Utility
FILE SEGMENT:            GRANTED
PRIMARY EXAMINER:        Rao, Deepak
LEGAL REPRESENTATIVE:    Dinner, Dara L., Venetianer, Stephen, Kinzig, Charles
                         M.
NUMBER OF CLAIMS:        26
EXEMPLARY CLAIM:         1
NUMBER OF DRAWINGS:      4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT:              1911
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Substituted quinazolinone compounds of formula (I) and compositions thereof for use in therapy as CSBP/p38 kinase inhibitors. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 2 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2005:254790 USPATFULL
TITLE: Heteropolymer complexes and methods for their use
INVENTOR(S): Taylor, Ronald P., Keswick, VA, UNITED STATES
Craig, Maria L., Shipman, VA, UNITED STATES
Hahn, Chang S., Charlottesville, VA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005221284	A1	20051006	
APPLICATION INFO.:	US 2003-484374	A1	20020717	(10)
	WO 2002-US23141		20020717	
			20041229	PCT 371 date

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-305989P	20010717 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2942
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an improved heteropolymer complex. The improved heteropolymer complex comprises a first monoclonal antibody specific for a C3b-like receptor (known as complement receptor (CR1) or CD35 in primates and Factor H in other mammals, e.g., dog, mouse, rat, pig, rabbit) site chemically crosslinked (covalently linked) to a second monoclonal antibody, in which the isotype of at least the second monoclonal antibody is the isotype having the highest affinity for the Fc receptor, e.g., in humans, IgG1 or IgG3. The present invention also relates to methods for immune clearance of an antigen in a mammal via the C3b-like receptor comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating or preventing viral infection or microbial infection in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating or preventing septic shock in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention also relates to methods for treating cancer in a mammal comprising administering to said mammal an improved heteropolymer complex of the invention. The present invention further relates to pharmaceutical compositions for the treatment or prevention of viral infection, microbial infection, septic shock, and cancer comprising an improved heteropolymer complex of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 3 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2005:87887 USPATFULL
TITLE: 3,4-Dihydro-(1H)-quinazolin-2-ones and their use as

CSBP/p38 kinase inhibitors
INVENTOR(S): Adams, Jerry L., Wayne, PA, UNITED STATES
Bower, Michael J., Audubon, PA, UNITED STATES
Hall, Ralph, Villanova, PA, UNITED STATES
Griswold, Don Edgar, North Wales, PA, UNITED STATES
Underwood, David C., Ambler, PA, UNITED STATES
PATENT ASSIGNEE(S): SmithKline Beecham Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005075352	A1	20050407
APPLICATION INFO.:	US 2004-884788	A1	20040702 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-129889, filed on 10 May 2002, GRANTED, Pat. No. US 6759410 A 371 of International Ser. No. WO 2000-US31908, filed on 21 Nov 2000, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-167113P	19991123 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, Corporate Intellectual Property - UW 2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 2061
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel substituted quinazoline compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:227934 USPATFULL
TITLE: Use of at least one glycoinhibitor substance
INVENTOR(S): Natunen, Jari, Vantaa, FINLAND
Miller-Podraza, Halina, Vastra Frolunda, SWEDEN
Teneberg, Susann, Hindas, SWEDEN
Angstrom, Jonas, Goteborg, SWEDEN
Karlsson, Karl-Anders, Goteborg, SWEDEN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004176320	A1	20040909
APPLICATION INFO.:	US 2003-482045	A1	20031229 (10)
	WO 2002-FI574		20020628

	NUMBER	DATE	
PRIORITY INFORMATION:	FI 2001-1402	20010629	<--
	FI 2001-1403	20010629	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
NUMBER OF CLAIMS: 66
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 2697
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of a glycosidase inhibitor for the manufacture of a medicament for the treatment of a disease, wherein glycosidase enzymes hydrolyze glycoconjugates of a patient to reveal neutral glycan receptors of an pathogenic agent, and wherein the revealed neutral glycan receptor comprise a oligosaccharide sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 5 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:168043 USPATFULL
TITLE: 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
INVENTOR(S): Adams, Jerry L., Wayne, PA, United States
Bower, Michael J., Audubon, PA, United States
Hall, Ralph, Villanova, PA, United States
Griswold, Don Edgar, North Wales, PA, United States
Underwood, David C., Ambler, PA, United States
PATENT ASSIGNEE(S): SmithLine Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE		
PATENT INFORMATION:	US 6759410	B1	20040706		
	WO 2001037837		20010531		<--
APPLICATION INFO.:	US 2002-129889		20020510	(10)	
	WO 2000-US31908		20001121		

	NUMBER	DATE		
PRIORITY INFORMATION:	US 1999-167113P	19991123	(60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Rao, Deepak
LEGAL REPRESENTATIVE: Kinzig, Charles M., Venetianer, Stephen, Dinner, Dara L.
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolines of formula (1), or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, and methods of using the same for treating viral infection or as an assay standard or reagent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 6 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:127487 USPATFULL
TITLE: Inhibitors of neuraminidases
INVENTOR(S): Maring, Clarence J., Palatine, IL, UNITED STATES
Gu, Yu Gui, Grayslake, IL, UNITED STATES
Chen, Hui-Ju, Grayslake, IL, UNITED STATES
Chen, Yuanwei, North Haven, CT, UNITED STATES
Degoey, David A., Kenosha, WI, UNITED STATES

Flosi, William J., Des Plaines, IL, UNITED STATES
Giranda, Vincent L., Gurnee, IL, UNITED STATES
Grampovnik, David J., Waukegan, IL, UNITED STATES
Kati, Warren M., Gurnee, IL, UNITED STATES
Kempf, Dale J., Libertyville, IL, UNITED STATES
Kennedy, April, Boulder, CO, UNITED STATES
Klein, Larry L., Lake Forest, IL, UNITED STATES
Krueger, Allan C., Gurnee, IL, UNITED STATES
Lin, Zhen, Gurnee, IL, UNITED STATES
Madigan, Darold L., Elk Grove Village, IL, UNITED STATES
McDaniel, Keith F., Wauconda, IL, UNITED STATES
Muchmore, Steven W., Libertyville, IL, UNITED STATES
Sham, Hing L., Mundelein, IL, UNITED STATES
Stewart, Kent D., Gurnee, IL, UNITED STATES
Stoll, Vincent S., Libertyville, IL, UNITED STATES
Sun, Minghua, Libertyville, IL, UNITED STATES
Tu, Noah P., Gurnee, IL, UNITED STATES
Wagenaar, Frank L., Gurnee, IL, UNITED STATES
Wang, Gary T., Niles, IL, UNITED STATES
Wang, Sheldon, Grayslake, IL, UNITED STATES
Wiedeman, Paul E., Deerfield, IL, UNITED STATES
Xu, Yibo, New Milford, CT, UNITED STATES
Yeung, Ming C., Grayslake, IL, UNITED STATES
Zhao, Chen, Libertyville, IL, UNITED STATES
Hanessian, Stephen, Beaconsfield, CANADA
Bayrakdarian, Malken, Verdun, CANADA
Luo, Xuehong, Montreal, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004097471	A1	20040520
	US 6831096	B2	20041214
APPLICATION INFO.:	US 2002-253152	A1	20020924 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-421787, filed on 19 Oct 1999, GRANTED, Pat. No. US 6455571 Continuation-in-part of Ser. No. US 1999-282139, filed on 31 Mar 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-82828P	19980423 (60) <--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEVEN F. WEINSTOCK, ABBOTT LABORATORIES, 100 ABBOTT PARK ROAD, DEPT. 377/AP6A, ABBOTT PARK, IL, 60064-6008
NUMBER OF CLAIMS: 114
EXEMPLARY CLAIM: 1
LINE COUNT: 14823
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compounds of the formula: ##STR1##

which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 7 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:126486 USPATFULL
TITLE: Novel receptors for $1(helicobater pyroli) and use thereof
INVENTOR(S): Miller-Podraza, Halina, UNITED STATES
Teneberg, Susann, Hind?aring;s, SWEDEN
Angstrom, Jonas, Goteb?ouml;rg, SWEDEN
Karlsson, Karl-Anders, G?ouml;teborg, SWEDEN
Natunen, Jari, Vantaa, SWEDEN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004096465	A1	20040520	
APPLICATION INFO.:	US 2003-466415	A1	20031029	(10)
	WO 2002-FI43		20020118	

	NUMBER	DATE	
PRIORITY INFORMATION:	FI 2001-118	20010119	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Page(s)
LINE COUNT: 2290
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention describes a substance or a receptor comprising Helicobacter pylori binding oligosaccharide sequence [Gal(A).sub.q(NAc).sub.r/Glc(A).sub.q(NAc).sub.rα3/β3].sub.s[Galβ4GlcNAcβ3].sub.tGalβ4Glc(NAc).sub.u wherein q, r, s, t, and u are each independently 0 or 1, and the use thereof in, e.g., pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 8 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:83172 USPATFULL
TITLE: Active agent delivery systems and methods for protecting and administering active agents
INVENTOR(S): Piccariello, Thomas, Blacksburg, VA, UNITED STATES
Kirk, Randal J., Radford, VA, UNITED STATES
Olon, Lawrence P., Bristol, TN, UNITED STATES
PATENT ASSIGNEE(S): New River Pharmaceuticals Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004063628	A1	20040401	
APPLICATION INFO.:	US 2002-156527	A1	20020529	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-986426, filed on 8 Nov 2001, PENDING Continuation-in-part of Ser. No. US 1999-411238, filed on 4 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-265415, filed on 10 Mar 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-642820, filed on 22 Aug 2000, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	WO 2000-US5693	20000306	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUNTON & WILLIAMS, INTELLECTUAL PROPERTY DEPARTMENT, 1900 K STREET, N.W., SUITE 1200, WASHINGTON, DC, 20006-1109
NUMBER OF CLAIMS: 56
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 10108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 9 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2004:70771 USPATFULL
TITLE: Novel compounds and methods for synthesis and therapy
INVENTOR(S): Bischofberger, Norbert W., San Carlos, CA, UNITED STATES
Dahl, Terrence C., Sunnyvale, CA, UNITED STATES
Hitchcock, Michael J. M., San Mateo, CA, UNITED STATES
Kim, Choung U., San Carlos, CA, UNITED STATES
Lew, Willard, San Mateo, CA, UNITED STATES
Liu, Hongtao, Foster City, CA, UNITED STATES
Mills, Roger G., Menlo Park, CA, UNITED STATES
Williams, Matthew A., Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004053999	A1	20040318
APPLICATION INFO.:	US 2003-628773	A1	20030728 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-153964, filed on 16 Sep 1998, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-60195P	19970926 (60)	<--
	US 1997-59308P	19970917 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GILEAD SCIENCES INC, 333 LAKESIDE DR, FOSTER CITY, CA, 94404
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 12454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with

labels, and assay methods for detecting neuraminidase activity are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 10 OF 18 USPATFULL on STN

ACCESSION NUMBER:	2004:30625 USPATFULL			
TITLE:	Use of il-8 protein modulators in the treatment of viral infections			
INVENTOR(S):	Dillon, Susan B, Wayne, PA, UNITED STATES Tal-Singer, Ruth, Collegeville, PA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004022762	A1	20040205	
APPLICATION INFO.:	US 2003-381066	A1	20030319	(10)
	WO 2001-US30222		20010925	
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2000-60234914		20000925	<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939			
NUMBER OF CLAIMS:	13			
EXEMPLARY CLAIM:	1			
LINE COUNT:	598			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to the novel use of an IL-8 protein modulator for the treatment of human virus infections and associated symptom exacerbations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 11 OF 18 USPATFULL on STN

ACCESSION NUMBER:	2003:258666 USPATFULL			
TITLE:	Novel heterocyclic antibacterial compounds			
INVENTOR(S):	Zhi, Chengxin, Worcester, MA, UNITED STATES Wright, George E., Worcester, MA, UNITED STATES			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003181719	A1	20030925	
	US 6777420	B2	20040817	
APPLICATION INFO.:	US 2002-173376	A1	20020617	(10)
	NUMBER		DATE	
PRIORITY INFORMATION:	US 2001-298534P		20010615 (60)	<--
	US 2002-348839P		20020114 (60)	
	US 2002-349837P		20020117 (60)	
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	Leon R. Yankwich, Esq., YANKWICH & ASSOCIATES, 201 Broadway, Cambridge, MA, 02139			
NUMBER OF CLAIMS:	39			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	4 Drawing Page(s)			

LINE COUNT: 3680
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides heterocyclic organic compounds that inhibit bacterial DNA polymerase IIIC and type II bacterial topoisomerase. The invention further provides compounds that are useful as intermediates in the synthesis of such heterocyclic organic compounds. Syntheses and uses of such heterocyclic organic molecules are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 12 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:190770 USPATFULL
TITLE: Neuraminidase inhibitors
INVENTOR(S): Maring, Clarence J., Palatine, IL, United States
Giranda, Vincent L., Gurnee, IL, United States
Gu, Yu Gui, Libertyville, IL, United States
Hanessian, Stephen, Beaconsfield, CANADA
Kempf, Dale J., Libertyville, IL, United States
Madigan, Darold L., Elk Grove Village, IL, United States
Stewart, Kent, Gurnee, IL, United States
Stoll, Vincent S., Libertyville, IL, United States
Sun, Minghua, Libertyville, IL, United States
Wang, Gary T., Niles, IL, United States
Wang, Jianchio, Montreal, CANADA
Zhao, Chen, Libertyville, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6593314	B1	20030715	
APPLICATION INFO.:	US 2000-668245		20000922	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-160350P	19991019 (60)	<--
	US 1999-161780P	19991027 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Zucker, Paul A.
LEGAL REPRESENTATIVE: Donner, B. Coregory
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1,14
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5230
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides compounds of formula Ia and Ib ##STR1##

or a pharmaceutically acceptable salt, prodrug, or ester thereof, useful in the inhibition of neuraminidase enzymes from disease-causing microorganisms, especially influenza neuraminidase, pharmaceutical formulations containing same, processes and intermediates for preparing said compounds, as well as methods of using said compounds, including preventing and treating diseases caused by microorganisms having said neuraminidase enzyme.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 13 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:148754 USPATFULL
TITLE: Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
INVENTOR(S): Taylor, Ronald, Charlottesville, VA, United States
Nardin, Alessandra, Paris, FRANCE
Sutherland, William M., Earlysville, VA, United States
Sokoloff, Mitchell H., Hinsdale, IL, United States
Chung, Leland, Lovingston, VA, United States
PATENT ASSIGNEE(S): The University of Virginia Patent Foundation, Charlottesville, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6572856	B1	20030603	
APPLICATION INFO.:	US 2000-724620		20001128 (9)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-392500, filed on 9 Sep 1999			
	NUMBER		DATE	
PRIORITY INFORMATION:	US 1998-99782P		19980910 (60)	<--
	US 1999-123786P		19990311 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Canella, Karen A.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3704
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the treatment and prevention of cancer, viral infections and microbial infections by the administration of anti-C3b(i) antibodies. The present invention also relates to methods of treating and preventing cancer, viral infection, or microbial infection in an animal comprising administering to said animal IgG antibodies, IgM antibodies and/or complement components in combination with antibodies specific for C3b(i). The present invention also relates methods of treating and preventing cancer, viral infection or microbial infection in an animal comprising administrating said animal antibodies that immunospecifically bind to one or more cancer cell antigens, viral antigens or microbial antigens, respectively, in combination with antibodies immunospecific for C3b(i). The present invention further relates to the detection, imaging, diagnosis and monitoring of cancer utilizing C3b(i) specific antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 14 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:50834 USPATFULL
TITLE: Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
INVENTOR(S): Chen, Shu-Hsia, New York, NY, UNITED STATES
Pan, Ping-Yan, New York, NY, UNITED STATES
Woo, Savio L.C., New York, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003035790	A1	20030220
APPLICATION INFO.:	US 2002-165643	A1	20020607 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-735296, filed on 14 Jan 2000, PENDING

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-115992P	19990115 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 6417
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compositions comprising compounds which augment activated immune cells, such as T-cells, dendritic cells and natural killer ("NK") cells, and methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising the administration of said compositions to said subject. In particular, the present invention relates to methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising administrating to said subject one or more compounds that activate one or more cytokine receptors and one or more compounds that activate one or more co-stimulatory molecules expressed by activated immune cells. The present invention also relates to compositions and kits comprising a compound that activates one or more cytokine receptors and a compound that activates one or more co-stimulatory molecules expressed by activated immune cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 15 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:40707 USPATFULL
TITLE: Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
INVENTOR(S): Maring, Clarence J., Palatine, IL, United States
Chen, Yuanwei, North Haven, CT, United States
Degoey, David A., Kenosha, WI, United States
Giranda, Vincent L., Gurnee, IL, United States
Grampovnik, David J., Waukegan, IL, United States
Gu, Yu Gui, Grayslake, IL, United States
Kati, Warren M., Gurnee, IL, United States
Kempf, Dale J., Libertyville, IL, United States
Kennedy, April, Grayslake, CO, United States
Krueger, Allan C., Gurnee, IL, United States
Lin, Zhen, Gurnee, IL, United States
Madigan, Darold L., Elk Grove Village, IL, United States
Muchmore, Steven W., Libertyville, IL, United States
Sham, Hing L., Mundelein, IL, United States
Stewart, Kent D., Gurnee, IL, United States
Stoll, Vincent S., Libertyville, IL, United States
Sun, Minghua, Libertyville, IL, United States
Wang, Gary T., Niles, IL, United States

Wang, Sheldon, Grayslake, IL, United States
Yeung, Ming C., Grayslake, IL, United States
Zhao, Chen, Libertyville, IL, United States
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6518305	B1	20030211
APPLICATION INFO.:	US 1999-422093		19991019 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-282138, filed on 31 Mar 1999, now abandoned

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-82843P	19980423 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Powers, Fiona T.
LEGAL REPRESENTATIVE: Donner, B. Gregory
NUMBER OF CLAIMS: 110
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 6448
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are compounds of the formula: ##STR1##

which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 16 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2003:13338 USPATFULL
TITLE: Methods of preventing and treating microbial infections
INVENTOR(S): Baker, Jr., James R., Ann Arbor, MI, United States
Hamouda, Tarek, Ypsilanti, MI, United States
Shih, Amy, Ann Arbor, MI, United States
Myc, Andrzej, Ann Arbor, MI, United States
PATENT ASSIGNEE(S): Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6506803	B1	20030114
APPLICATION INFO.:	US 2000-561111		20000428 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-474866, filed on 30 Dec 1999

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1999-131638P	19990428 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Fubara, Blessing
LEGAL REPRESENTATIVE: Medlen & Carroll, LLP

NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Figure(s); 35 Drawing Page(s)
LINE COUNT: 3200
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods and compositions for inactivating bacteria including bacterial spores using an oil-in-water emulsion are provided. The oil-in-water emulsion comprises an oil, a surfactant and an organic phosphate-based solvent. These methods can be used to inactivate a wide variety of microorganisms including bacteria, bacterial spores, fungi, fungal spores and enveloped viruses.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 17 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2002:246771 USPATFULL
TITLE: Inhibitors of neuraminidases
INVENTOR(S): Maring, Clarence J., Palatine, IL, United States
Gu, Yu Gui, Grayslake, IL, United States
Chen, Hui-Ju, Grayslake, IL, United States
Chen, Yuanwei, North Haven, CT, United States
Degoey, David A., Kenosha, WI, United States
Flosi, William J., Des Plaines, IL, United States
Giranda, Vincent L., Gurnee, IL, United States
Grampovnik, David J., Waukegan, IL, United States
Kati, Warren M., Gurnee, IL, United States
Kempf, Dale J., Libertyville, IL, United States
Kennedy, April, Grayslake, IL, United States
Klein, Larry L., Lake Forest, IL, United States
Krueger, Allan C., Gurnee, IL, United States
Lin, Zhen, Gurnee, IL, United States
Madigan, Darold L., Elk Grove Village, IL, United States
McDaniel, Keith F., Grayslake, IL, United States
Muchmore, Steven W., Libertyville, IL, United States
Sham, Hing L., Mundelein, IL, United States
Stewart, Kent D., Gurnee, IL, United States
Stoll, Vincent S., Libertyville, IL, United States
Sun, Minghua, Libertyville, IL, United States
Tu, Noah P., Gurnee, IL, United States
Wagenaar, Frank L., Gurnee, IL, United States
Wang, Gary T., Niles, IL, United States
Wang, Sheldon, Grayslake, IL, United States
Wiedeman, Paul E., Deerfield, IL, United States
Xu, Yibo, Ridgefield, CT, United States
Yeung, Ming C., Grayslake, IL, United States
Zhao, Chen, Libertyville, IL, United States
Hanessian, Stephen, Beaconsfield, CANADA
Bayrakdarian, Malken, Verdun, CANADA
Luo, Xuehong, Montreal, CANADA
PATENT ASSIGNEE(S): Abbott Laboratories, Abbott Park, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6455571	B1	20020924
APPLICATION INFO.:	US 1999-421787		19991019 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-282139, filed on 31 Mar 1999, now abandoned

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-82828P	19980423 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Lambkin, Deborah C.
LEGAL REPRESENTATIVE: Donner, B. Gregory
NUMBER OF CLAIMS: 115
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 14553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are compounds of the formula: ##STR1##

which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and treating diseases caused by microorganisms having a neuraminidase, processes for preparing the compounds and synthetic intermediates used in these processes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 18 OF 18 USPATFULL on STN
ACCESSION NUMBER: 2001:205946 USPATFULL
TITLE: Use of PDE-4-specific inhibitors to reduce the severity of a bacterial infection after a respiratory viral infection
INVENTOR(S): DeMarsh, Peter L., West Chester, PA, United States
Dillon, Susan B., Alamo, CA, United States
Woodnutt, Gary, Chester Springs, PA, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001041739	A1	20011115	
	US 6436971	B2	20020820	
APPLICATION INFO.:	US 2001-779401	A1	20010208	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-181385P	20000209 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 463
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a method for the prophylaxis of or reducing the severity of post-viral bacterial infection by administering a PDE 4-specific inhibitor prior to or during the course of a viral infection or thereafter during the course of the bacterial infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> d his ful

     (FILE 'HOME' ENTERED AT 11:04:56 ON 28 APR 2006)

     FILE 'HCAPLUS' ENTERED AT 11:10:45 ON 28 APR 2006
                E MCCULLERS JONATHAN
                E MCCULLERS JONATHAN/AU
L1           17 SEA ABB=ON  ("MCCULLERS J"/AU OR "MCCULLERS JONATHAN"/AU OR
                "MCCULLERS JONATHAN A"/AU)
L2            7 SEA ABB=ON  L1 AND ?NEURAMINIDASE?
L3            2 SEA ABB=ON  L2 AND ?BACT?(W)?INFECT?
L4              ANALYZE L3 2 CT :      34 TERMS

     FILE 'REGISTRY' ENTERED AT 11:19:32 ON 28 APR 2006
L5            3 SEA ABB=ON  (OSELTAMIVIR PHOSPHATE OR ZANAMIVIR OR RJW-270201
                OR RJW 270201 OR RJW270201 OR BCX-1812 OR BCX1812 OR BCX 1812)
                E RJW 270201/CN
                E RJW270201/CN

     FILE 'HCAPLUS' ENTERED AT 11:21:55 ON 28 APR 2006
L6          470 SEA ABB=ON  (L5 OR OSELTAMIVIR PHOSPHATE OR ZANAMIVIR OR
                RJW-270201 OR RJW 270201 OR RJW270201 OR BCX-1812 OR BCX1812
                OR BCX 1812)
L7            0 SEA ABB=ON  L6 AND (?BACT?(3A)?PNEUMONIA?(P)(?VIRAL?'OR
                ?VIRUS?))
L8          414 SEA ABB=ON  L6 AND (?BACT? OR ?PNEUMONIA? OR ?VIRAL? OR
                ?VIRUS?)
L9           17 SEA ABB=ON  L8 AND (?PNEUMONIA? AND (?VIRUS? OR ?VIRAL?))

     FILE 'REGISTRY' ENTERED AT 11:29:28 ON 28 APR 2006
L10          18 SEA ABB=ON  (CEFTRIAXONE OR CEFOTAXIME OR VANCOMYCIN OR
                MEROPENEM OR CEFEPIME OR CEFTAZIDIME OR CEFUROXIME OR NAFCILLIN
                 OR OXACILLIN OR AMPICILLIN OR TICARCILLIN OR TIMENTIN OR
                UNASYN OR AZITHROMYCIN OR TRIMETHOPRIM SULFAMETHOXAZOLE OR
                CLINDAMYCIN OR CIPROFLOXACIN OR LEVOFLOXACIN OR SYNERCID)/CN
L11          15 SEA ABB=ON  (AMOXICILLIN OR AUGMENTIN OR CEFUROXIME OR
                TRIMETHOPRIM SULFAMETHOXAZOLE OR AZITHROMYCIN OR CLINDAMYCIN
                OR DICLOXACILLIN OR CIPROFLOXACIN OR LEVOFLOXACIN OR CEFIXIME
                OR CEFPODOXIME OR LORACARBEF OR CEFADROXIL OR CEFABUTIN OR
                CEFDINIR OR CEPHRADINE)/CN
L12          28 SEA ABB=ON  L10 OR L11

     FILE 'HCAPLUS' ENTERED AT 11:33:19 ON 28 APR 2006
L13       48777 SEA ABB=ON  (CEFTRIAXONE OR CEFOTAXIME OR VANCOMYCIN OR
                MEROPENEM OR CEFEPIME OR CEFTAZIDIME OR CEFUROXIME OR NAFCILLIN
                 OR OXACILLIN OR AMPICILLIN OR TICARCILLIN OR TIMENTIN OR
                UNASYN OR AZITHROMYCIN OR TRIMETHOPRIM SULFAMETHOXAZOLE OR
                CLINDAMYCIN OR CIPROFLOXACIN OR LEVOFLOXACIN OR SYNERCID)
L14       52930 SEA ABB=ON  L13 OR AMOXICILLIN OR AUGMENTIN OR CEFUROXIME OR
                TRIMETHOPRIM SULFAMETHOXAZOLE OR AZITHROMYCIN OR CLINDAMYCIN
                OR DICLOXACILLIN OR CIPROFLOXACIN OR LEVOFLOXACIN OR CEFIXIME
                OR CEFPODOXIME OR LORACARBEF OR CEFADROXIL OR CEFABUTIN OR
                CEFDINIR OR CEPHRADINE
L15           7 SEA ABB=ON  L9 AND (?ANTIBIOTIC? OR L14)
L16           2 SEA ABB=ON  L15 AND (PRD<20010927 OR PD<20010927)

     FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 11:37:45 ON
     28 APR 2006
L17          98 SEA ABB=ON  L15
```

2 cits from CA Plus

```
L18          98 DUP REMOV L17 (0 DUPLICATES REMOVED)
L19           1 SEA ABB=ON  L18 AND ?SECONDARY?(W) ?BACT?(W) ?INFECT?
L20          98 SEA ABB=ON  L18 AND (?BACT?(W) ?INFECT? OR ?PNEUMONIA?)
L21           4 SEA ABB=ON  L20 AND ?NEURAMINIDASE?(W) ?INHIBIT?
```

4 cits from above database

```
FILE 'USPATFULL' ENTERED AT 11:42:42 ON 28 APR 2006
L22          18 SEA ABB=ON  L15 AND (PRD<20010927 OR PD<20010927)
```

18 cits from USPatFull

```
FILE HOME

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 21, 2006 (20060421/UP).

FILE HCAPLUS

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 Apr 2006  VOL 144 ISS 19
FILE LAST UPDATED: 27 Apr 2006  (20060427/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 APR 2006  HIGHEST RN 882066-77-5
DICTIONARY FILE UPDATES:  27 APR 2006  HIGHEST RN 882066-77-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*************************************************************
*                                                           *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                           *
*************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.
```

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE MEDLINE
FILE LAST UPDATED: 27 APR 2006 (20060427/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 26 April 2006 (20060426/ED)

FILE EMBASE
FILE COVERS 1974 TO 28 Apr 2006 (20060428/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE JAPIO
FILE LAST UPDATED: 3 APR 2006 <20060403/UP>
FILE COVERS APRIL 1973 TO DECEMBER 22, 2005

>>> GRAPHIC IMAGES AVAILABLE <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE. USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION ABOUT THE IPC REFORM <<<

FILE JICST-EPLUS

FILE COVERS 1985 TO 24 APR 2006 (20060424/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 Apr 2006 (20060427/PD)
FILE LAST UPDATED: 27 Apr 2006 (20060427/ED)
HIGHEST GRANTED PATENT NUMBER: US7036150
HIGHEST APPLICATION PUBLICATION NUMBER: US2006090232
CA INDEXING IS CURRENT THROUGH 27 Apr 2006 (20060427/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 Apr 2006 (20060427/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

=> d ibib abs ind l3 1-2

L3 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:38038 HCAPLUS
DOCUMENT NUMBER: 142:169102
TITLE: The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae
AUTHOR(S): Alymova, Irina V.; Portner, Allen; Takimoto, Toru; Boyd, Kelli L.; Babu, Y. Sudhakara; McCullers, Jonathan A.
CORPORATE SOURCE: Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA
SOURCE: Antimicrobial Agents and Chemotherapy (2005), 49(1), 398-405
CODEN: AMACCQ; ISSN: 0066-4804
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB An association exists between respiratory viruses and bacterial infections. Prevention or treatment of the preceding viral infection is a logical goal for reducing this important cause of morbidity and mortality. The ability of the novel, selective parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 to prevent the synergism between a paramyxovirus and Streptococcus pneumoniae was examined in this study. A model of secondary bacterial pneumonia after infection with a recombinant Sendai virus whose hemagglutinin-neuraminidase gene was replaced with that of human parainfluenza virus type 1 [rSV(hHN)] was established in mice. Challenge of mice with a sublethal dose of S. pneumoniae 7 days after a sublethal infection with rSV(hHN) (synergistic group) caused 100% mortality. Bacterial infection preceding viral infection had no effect on survival. The mean bacterial titers in the synergistic group were significantly higher than in mice infected with bacteria only. The virus titers were similar in mice infected with rSV(hHN) alone and in dually infected mice. Intranasal administration of BCX 2798 at 10 mg/kg per day to the synergistic group of mice starting 4 h before virus infection protected 80% of animals from death. This effect was accompanied by a significant reduction in lung viral and bacterial titers. Treatment of mice 24 h after the rSV(hHN) infection showed no protection against synergistic lethality. Together, our results indicate that parainfluenza viruses can prime for secondary bacterial infections. Prophylaxis of parainfluenza virus infections with antivirals might be an effective strategy for prevention of secondary bacterial complications in humans.
CC 1-5 (Pharmacology)
ST parainfluenza virus hemagglutinin neuraminidase inhibitor BCX2798 Streptococcus
IT Infection
(bacterial; novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae)
IT Antiviral agents
Human
Human parainfluenza virus 1
Paramyxovirus
Streptococcus pneumoniae
(novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae)

IT Infection
(viral; novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae)
IT 464180-00-5, BCX 2798
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae)
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:261602 HCAPLUS
DOCUMENT NUMBER: 138:265609
TITLE: Use of neuraminidase inhibitors to prevent flu-associated bacterial infections
INVENTOR(S): McCullers, Jonathan A.
PATENT ASSIGNEE(S): St. Jude Children's Research Hospital, USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026567	A2	20030403	WO 2002-US29417	20020917
WO 2003026567	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004248825	A1	20041209	US 2004-809127	20040325
PRIORITY APPLN. INFO.:			US 2001-325615P	P 20010927
			WO 2002-US29417	A1 20020917

AB The invention provides a novel use for neuraminidase inhibitors in chemoprophylactic and treatment methods for the prevention, attenuation, and treatment of bacterial infections that may occur in association with, or as a sequelae of, viral influenza. The prophylactic methods of the invention are particularly suitable for the prevention of secondary bacterial infections, such as, but not limited to, infections of the lower respiratory tract (e.g., pneumonia), middle ear infections (e.g., otitis media), and bacterial sinusitis. The treatment methods are suitable for use in protocols designed to attenuate or treat bacterial infections that occur concurrent with, or as a sequelae of, the flu.
IC ICM A61K
CC 1-5 (Pharmacology)
ST neuraminidase inhibitor influenza assocd bacterial infection treatment
IT Infection

Pneumonia
(bacterial; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Development, mammalian postnatal
(child; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Therapy
(chronic care facility; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Cardiovascular system, disease
Lung, disease
(chronic; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Metabolism, animal
(disorder, chronic; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Lung
(epithelium, pneumococcal receptors; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Drugs
Human immunodeficiency virus
(immunosuppression from; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Lung, disease
(infection; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Respiratory system, disease
(lower respiratory tract infection; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Infection
(lower respiratory tract; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Sialic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lung epithelial cell, influenza virus-mediated cleavage of; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Hemoglobins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metabolic disorders, hemoglobinopathy; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Aging, animal
Antibacterial agents
Diabetes mellitus
Drug delivery systems
Haemophilus influenzae
Human
Immunosuppression
Influenza
Influenza A virus
Influenza virus
Kidney, disease
Moraxella catarrhalis
Mycoplasma
Pregnancy
Staphylococcus aureus
Streptococcus pneumoniae
(neuraminidase inhibitors to prevent flu-associated bacterial infections)

IT Antibiotics
(neuraminidase inhibitors to prevent flu-associated bacterial infections, and use with antibiotics)
IT Drug delivery systems
(oral; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Ear, disease
Inflammation
(otitis media; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pneumococcal, lung epithelium; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Pneumonia
(pneumococcal; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Epithelium
(pulmonary, pneumococcal receptors; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Infection
(pulmonary; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT Inflammation
Respiratory system, disease
(sinusitis, bacterial; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT 50-78-2, Aspirin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(long-term therapy; neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT 9001-67-6, Neuraminidase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT 139110-80-8, Zanamivir 187227-45-8, GS 4071 196618-13-0, GS 4104 204255-11-8, Oseltamivir phosphate 330600-85-6, BCX 1812
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuraminidase inhibitors to prevent flu-associated bacterial infections)
IT 66-79-5, Oxacillin 69-53-4, Ampicillin 147-52-4, Nafcillin 1404-90-6, Vancomycin 3116-76-5, Dicloxacillin 8064-90-2 18323-44-9, Clindamycin 26787-78-0, Amoxicillin 34787-01-4, Ticarcillin 38821-53-3, Cephradine 50370-12-2, Cefadroxil 55268-75-2, Cefuroxime 63527-52-6, Cefotaxime 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 74469-00-4, Augmentin 76470-66-1, Loracarbef 76497-13-7, Unasyn 79198-29-1, Amoxicillin-clavulanic acid mixture 79350-37-1, Cefixime 80210-62-4, Cefpodoxime 83905-01-5, Azithromycin 85721-33-1, Ciprofloxacin 86482-18-0, Timentin 88040-23-7, Cefepime 91832-40-5, Cefdinir 94935-63-4, Ampicillin-sulbactam mixture 96036-03-2, Meropenem 100986-85-4, Levofloxacin 126602-89-9, Synercid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuraminidase inhibitors to prevent flu-associated bacterial infections, and use with antibiotics)